Table of Contents
WSSV Antiviral Solutions Break Barriers in Shrimp Health: Innocreate Bioscience CEO Dr. Jeff Hsu Publishes Landmark Research
WSSV Antiviral Solutions are the “holy grail” of the shrimp farming industry, and Innocreate Bioscience is proud to announce a major leap forward in this scientific quest. Our Founder and CEO, Dr. Jeff Chia-Kai Hsu, has officially published a significant research paper in the prestigious international journal, Aquaculture (ScienceDirect). This publication marks a major milestone in the global fight against the industry’s most devastating pathogen, the White Spot Syndrome Virus (WSSV).
The article, titled “Oral delivery of chitosan-encapsulated DNA vaccine confers protection against White Spot Syndrome Virus (WSSV) in Litopenaeus vannamei,” provides a comprehensive look at how biotechnology can be harnessed to create scalable WSSV Antiviral Solutions. For decades, WSSV has caused billions of dollars in losses worldwide; Dr. Hsu’s research offers a viable path toward preventing these outbreaks through innovative oral vaccination.
A 13-Year Journey of Innovation
The publication represents over a decade of dedication to aquatic health. Reflecting on the long road to this discovery, Dr. Hsu shared:
“This is one of our various attempts to combat the White Spot Syndrome Virus in shrimp. Thirteen years ago, we initiated this research, and today, we share with you the results of the delivery platform study completed years ago, combined with the verification of its antiviral infection efficacy.”
The study focuses on an innovative oral delivery platform using chitosan-encapsulated DNA. Chitosan, a natural polymer derived from crustacean shells, acts as a protective “envelope” for the DNA vaccine. This allows the vaccine to survive the shrimp’s digestive tract and be absorbed effectively. This technology is a breakthrough because it provides a practical way to offer shrimp protection without the need for individual injections—a method that is impossible at the scale of commercial farming.
The Science Behind the Breakthrough
To find effective WSSV Antiviral Solutions, the research team had to solve the problem of delivery. Unlike terrestrial livestock, vaccinating millions of shrimp individually is not an option. The oral delivery method developed by Dr. Hsu and his team means that protection can be administered through feed.
In the study, shrimp that received the chitosan-encapsulated DNA showed significantly higher survival rates when challenged with the virus compared to the control group. This confirms that the DNA vaccine successfully triggers the shrimp’s immune response, creating a biological barrier against the infection. This research shifts the focus from merely reacting to a disease to building intrinsic immunity within the stock.
Navigating a Shifting Regulatory Landscape
While the research was completed several years ago, the path to sharing it with the world was complicated by the evolving legalities of biotechnology. In the past, the development of DNA-based vaccines in aquaculture faced significant hurdles due to a lack of clear frameworks for genetically engineered health solutions.
“Previously, the development of such DNA vaccines was hindered by regulatory restrictions, slowing progress and stifling innovation,” Dr. Hsu explained. “However, the world today may have a greater understanding and acceptance of these technologies, especially as we seek more sustainable WSSV Antiviral Solutions that reduce the need for chemicals.”
With the global aquaculture industry now prioritizing biosecurity and seeking “green” alternatives to traditional treatments, the timing of this publication is critical. It provides a robust scientific foundation for future interventions that protect both the economic value of the crop and the environmental integrity of the surrounding water.
Innocreate’s Holistic Vision for Biosecurity
At Innocreate Bioscience, we believe that effective health management requires a multi-layered approach. While we are widely known for our early disease detection tools—such as our WOAH-registered iRP test kits—this research underscores our deeper commitment to the entire health lifecycle.
By combining rapid detection with innovative WSSV Antiviral Solutions, we provide a complete biosecurity loop. Detection tells you when the threat is near; vaccination ensures your stock is ready to fight back. We are not just identifying diseases; we are pioneering the science of how to stop them at the molecular level.
Gratitude and Future Outlook
This achievement was a collaborative effort. Innocreate Bioscience extends its heartfelt gratitude to the researchers, partners, and team members who participated in this 13-year journey.
As Innocreate continues to lead in early disease detection (such as our WOAH-registered iRP test kits), this research underscores our deeper commitment to comprehensive health management. We are not just identifying diseases; we are pioneering the science of how to stop them.
Read the full study on ScienceDirect: Oral delivery of chitosan-encapsulated DNA vaccine confers protection against WSSV
About Innocreate Bioscience
Innocreate Bioscience Co., Ltd. is a leader in aquatic health technology, specializing in the development of rapid, reliable, and accessible diagnostic tools. Its flagship WSSV RP Rapid Test Kit is a finalist for the 2025 Responsible Seafood Innovation Award, reflecting the company’s ongoing impact on global food security.
